(Q34604941)

3 August 2017

1 reference

title

Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1. (English)

1 reference

3 August 2017

Joshua S Hunt

1

1 reference

3 August 2017

Frank Romanelli

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 March 2009

1 reference

3 August 2017

1 reference

3 August 2017

volume

29

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

295-304

1 reference

HIV entry and its inhibition

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

Inhibiting HIV-1 entry with fusion inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

A new classification for HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

Assessing chemokine co-receptor usage in HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.3.295

21 January 2018

Identifiers

DOI

10.1592/PHCO.29.3.295

1 reference

3 August 2017

1 reference